Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Aquestive Therapeutics Q4 Earnings Call Highlights
04:49am, Saturday, 07'th Mar 2026
Aquestive Therapeutics (NASDAQ: AQST) executives used the company's fourth-quarter 2025 earnings call to outline a path forward for Anaphylm, its orally delivered epinephrine product candidate, follow
SAN DIEGO, March 6, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (N
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
ATLANTA, March 06, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). The lawsuit al
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
11:42am, Friday, 06'th Mar 2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jerse
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Aquestive Therapeutics
09:38am, Friday, 06'th Mar 2026
NEW YORK--(BUSINESS WIRE)---- $AQST #AQST--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the
Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit
07:14pm, Thursday, 05'th Mar 2026
SAN DIEGO--(BUSINESS WIRE)---- $AOST #Aquestive--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, I
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi and Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aquestive
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
01:15pm, Thursday, 05'th Mar 2026
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
09:35am, Thursday, 05'th Mar 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics
07:30pm, Wednesday, 04'th Mar 2026
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates
06:16pm, Wednesday, 04'th Mar 2026
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.19 per share a year ago.
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:01pm, Wednesday, 04'th Mar 2026
WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful im
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
09:13am, Tuesday, 03'rd Mar 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
08:13am, Saturday, 28'th Feb 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options
